APA

Saliba R. M., Sarantopoulos S., Kitko C. L., Pawarode A., Goldstein S. C., Magenau J., Alousi A. M., Churay T., Justman H., Paczesny S., Reddy P. & Couriel D. R. (20180322). B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. : Bone marrow transplantation.

Chicago

Saliba R M, Sarantopoulos S, Kitko C L, Pawarode A, Goldstein S C, Magenau J, Alousi A M, Churay T, Justman H, Paczesny S, Reddy P and Couriel D R. 20180322. B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. : Bone marrow transplantation.

Harvard

Saliba R. M., Sarantopoulos S., Kitko C. L., Pawarode A., Goldstein S. C., Magenau J., Alousi A. M., Churay T., Justman H., Paczesny S., Reddy P. and Couriel D. R. (20180322). B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. : Bone marrow transplantation.

MLA

Saliba R M, Sarantopoulos S, Kitko C L, Pawarode A, Goldstein S C, Magenau J, Alousi A M, Churay T, Justman H, Paczesny S, Reddy P and Couriel D R. B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. : Bone marrow transplantation. 20180322.